Related references
Note: Only part of the references are listed.The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases
Lorenzo Ferro Desideri et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2022)
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Charles C. Wykoff et al.
LANCET (2022)
Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes
Gurkaran S. Sarohia et al.
SURVEY OF OPHTHALMOLOGY (2022)
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Srinivas R. Sadda et al.
EYE (2020)
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration The AVENUE Phase 2 Randomized Clinical Trial
Jayashree Sahni et al.
JAMA OPHTHALMOLOGY (2020)
Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with Treat-and-Extend Regimen-Its Usefulness and Problems
Shinichiro Chujo et al.
JOURNAL OF CLINICAL MEDICINE (2020)
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA Forty-Eight-Week Outcomes
Bobak Bahrami et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2019)
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease
Rehan M. Hussain et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Rita Laiginhas et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2018)
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment A Secondary Analysis of a Randomized Clinical Trial
Neil M. Bressler et al.
JAMA OPHTHALMOLOGY (2018)
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab
Mohammed Ashraf et al.
OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2017)
Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
Susan B. Bressler et al.
JAMA OPHTHALMOLOGY (2016)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman et al.
OPHTHALMOLOGY (2010)
Share Paper
